‧DNA binding protein (DBP) was designed to raise site-selectivity of phiC31 integrase.
Introduction 1 2
Chromosomal integration enables sustained transgene expression and cell division-3 dependent replication of transgenes. Therefore, integrative vectors have often been applied to gene 4 therapies (Calos, 2006) , reprogramming (Takahashi and Yamanaka, 2006) , induction of differentiation 5 (Lacoste et al., 2009 ), tumor-model establishments (Carlson et al., 2005 ) and production of 6 recombinant proteins (Tomita et al., 2003) . PhiC31 integrase, a serine recombinase of Streptomyces 7 phage, is widely used for chromosomal integration (Calos, 2006) . In its natural context, phiC31 8 integrase integrates phage genomes into bacterial genomes by recombination between phage attP sites 9 and bacterial attB ones (Thorpe and Smith, 1998) . PhiC31 integrase can also react with pseudo-attP 10 sequences that partially match with bacterial attP sequences, and thereby integrate plasmid vectors 11 containing attB sequences (called "donor vectors") into the genomes of many organisms, including 12 yeasts (Thomason et al., 2001) , insects (Groth et al., 2004) , amphibians (Allen and Weeks, 2005) , birds 13 (Leghton et al., 2008) , and mammals, in both cultured cells (Groth et al., 2000 and Thyagarajan et al., 14 2001 ) and adult animals (Olivares et al., 2002) . Such attP or pseudo-attP-targeting characteristics of 15 phiC31 integrase-based vector systems enable site-specific integration, unlike other integrative vectors 16 including lentiviral vectors or Sleeping Beauty (Vink et al., 2009) , piggyBac (Nakanishi et al., 2010 17 and 2011 ), and Tol2 (Grabundzija et al., 2010 transposon-based vectors. Gene integration into or close 18 to endogenous genes can disrupt or dysregulate their function, and sometimes induces severe adverse 19 effects such as cancer (Hacein-Bey-Abina et al., 2003) . In addition, random integration of sites results 20 in a variegation of integrated transgene expression, which is called "position effect variegation" 21 (Robertson et al., 1995) . While some newer techniques, including transcription activator-like effector 22 nucleases (TALENs) (Cermak et al., 2011 and Miller et al., 2011) and clustered regularly interspaced 23 short palindromic repeats (CRISPR)/Cas9 (Cong et al., 2013 and Mali et al., 2013) , are available for 24 site-specific chromosomal integration, phiC31 integrase-based vector systems still remain useful 25 because it allows in vivo gene integration in adult mammals (Olivares et al., 2002) . However, phiC31 26 integrase-based vector systems are not sufficient in terms of site-specificity of integration, considering 27
To analyze phiC31 integrase-mediated integration sites, Hela-attPlex4R cells (5×10 4 cells) 23
were transfected with 500 ng of pTargetB2(4x)-LexA-Rluc. Two days later, the cells were transfected 24 with 500 ng of pCMV-int. XtremeGene9 was used for both transfections. From the next day, cells were 25 cultured in medium containing 3 µg/ml blasticidin S for 18 days. DNA was isolated from these cells 26 using a Genelute mammalian genomic DNA extraction kit, and digested using restriction enzyme NheI, 27 SpeI, and XbaI. After digestion by these restriction enzymes, the DNA was purified using a Genelute 1 PCR Clean-up Kit (Sigma-Aldrich Japan) and ligated using a Rapid DNA Dephos & Ligation Kit 2 (Roche Diagnostics) or Ligation convenience kit (Nippon Gene). The ligation products were used to 3 transform E. coli Strain DH5α or HST08. pDNA was purified from blasticidin-resistant E coli using 4 a PureYield plasmid Miniprep Kit. The nucleotide sequences of the pDNA were sequenced using a 5
BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies Japan, Tokyo, Japan) and 6 ABI3100xl (Life Technologies Japan). 7 8
Results

10
Vector design to analyze inter-plasmid integration 11
The phiC31 integrase-based vector system consists of two vector types. One is a donor 12 vector that contains the attB sequence, and the other is a helper vector that expresses phiC31 integrase. 13
PhiC31 integrase expressed by helper vectors integrates donor vectors into chromosomes. 14
To enhance the site-specificity of phiC31 integrase-mediated integration, we designed the 15 expression cassette of a dual DNA-binding protein which tethers the donor vector at the target 16 sequence. The dual DNA-binding protein contains a Gal4 DNA-binding domain and LexA DNA-17 binding domain, which recognize an upstream activation sequence (UAS) and a LexA operator 18 sequence, respectively. Here, the LexA operator sequence was assumed to be a model of binding 19 targets in chromosomes. Tethering of the donor vector by the dual DNA-binding protein limits phiC31 20 integrase-mediated integration to the attP sites close to its target sequence (Fig. 1) . pTargetB-LexA-21
Rluc was constructed as a donor vector, in which both the expression cassettes of the DNA-binding 22 protein and 4 copies of UAS were inserted in addition to the Renilla luciferase gene. The donor vector 23 named pTargetB-NLS-Rluc was also constructed as a negative control. pTargetB-NLS-Rluc was the 24 same as pTargetB-LexA-Rluc, except that it expressed a DNA-binding protein lacking the LexA DNA-25 binding domain. pAttB-UAS-Rluc was another negative control donor vector, which had no 26 expression cassette of DNA-binding protein. On the other hand, pCMV-int and pSV40-int were 27 8 constructed as helper vectors that express phiC31 integrase. To investigate whether the integration of 1 pTargetB-LexA-Rluc is dependent on the distance between the target sequence for the DNA-binding 2 protein and attP sequence, eight recipient vectors (i.e., pAttP-lex1~4F and 1~4R) having different 3 attP-sequence orientations and different distances between the LexA operator and attP sequences were 4 constructed (Fig. 2) . 5 6 Effect of the DNA-binding protein on the integration efficiency 7
It was preliminarily investigated whether binding of the DNA-binding protein to the donor 8 vector prevents phiC31 integrase from interacting with the donor vector. Following transfection of 9 HEK293 cells with pTargetB-NLS-Rluc or pAttB-UAS-Rluc and with or without pCMV-int, 10 sustainability of the gene expression of Rluc was evaluated as an indicator of integrations. When the 11 effect of co-transfection with pCMV-int on the Rluc expression was evaluated on day 12, the sustained 12 gene expression was enhanced by 2.32-fold and 1.45-fold in pTargetB-NLS-Rluc-transfected and 13 pAttB-UAS-Rluc-transfected cells, respectively (Fig. 3) . It should be remembered that the DNA-14 binding protein could be expressed and associated with the donor vector in pTargetB-NLS-Rluc, but 15 this was not the case in pAttB-UAS-Rluc. Nevertheless, the enhancement of sustained gene expression 16 by phiC31 integrase was not lower in pTargetB-NLS-Rluc. This suggests that phiC31 integrase-17 mediated integration was not inhibited even though the DNA-binding protein bound to the donor 18
vectors. 19 20
Integration site-specificity in inter-plasmid integration 21
The effects of the DNA-binding protein on the integration site-specificity were investigated 22 in an inter-plasmid integration assay. To avoid phiC31 integrase-mediated inter-plasmid integration 23 during the amplification process in E. coli (Thorpe and Smith, 1998), pSV40-int was used as a helper 24 vector instead of pCMV-int (Fig. 2) . pSV40-int was chosen because, unlike the CMV promoter, the 25 SV40 promoter does not express proteins in E. coli (Goussard et al., 2003) . A preliminary experiment 26 indicated that pSV40-int cannot integrate donor vectors in E. coli but can do so in Hela cells (data not 27 shown). 1 First, Hela cells were transfected simultaneously with pSV40-int as a helper vector, 2 pTargeB-NLS-Rluc or pTargetB-LexA-Rluc as donor vectors, and pAttP-lex1~4F and 1~4R as 3 recipient vectors. Two days later, DNA was extracted from these cells and transformed to E. coli. 4
Taking into account that the inter-plasmid integration products contain blasticidin-and kanamycin-5 resistance genes originated from donor and recipient vectors, respectively, transformed E. coli was 6 selected by both blasticidin and kanamycin. The inter-plasmid integration products extracted from E. 7 coli were digested with restriction enzymes and subjected to gel electrophoresis to determine to what 8 extent each recipient vector was integrated. Figure 4a and b shows the percentages of integration into 9 each recipient vector per total integration, and the ratio of the pTargetB-LexA-Rluc transfected group 10 per the pTargetB-NLS-Rluc group, respectively. pTargetB-LexA-Rluc was designed to express a 11 DNA-binding protein (i.e., the Gal4-LexA DNA-binding protein) that could bind to both the donor 12 and recipient vectors, whereas pTargetB-NLS-Rluc expressed a protein that bound only to the donor 13 vector. As shown in Fig. 4b , the percentage of integration into pAttP-lex4R, which has the smallest 14
LexA-attP distance of 219 bp, was increased 4.5-fold in the pTargetB-LexA-Rluc group. 15
16
Cell line establishment and vector construction for the analysis of chromosomal integration 17
Prior to the evaluation of Gal4-LexA DNA-binding protein-enhanced integration site-18 specificity in chromosomes, we established a stable cell line designated Hela-attPlex4R, in which both 19 the attP and LexA operator sequences were chromosomally integrated. pAttP-lex4R was selected for 20 the integration to establish Hela-attPlex4R, based on the results of the inter-plasmid integration assay 21 (Fig. 4) . At first, pAttP-lex4R was linearized and inserted into piggyBac transposon (hereafter pIR-22 attPlex4R). Then, pIR-attPlex4R together with the piggyBac transposase expression vector pFerH-23 PBTP were transfected into Hela cells to integrate the transposon containing the pAttP-lex4R-derived 24 sequence into chromosomes (Fig. 5) . Following selection, a stably integrated HeLa-attPlex4R cell 25 clone was obtained and subjected to quantitative evaluation of chromosomal integration. Integration 26 of attPlex4R sequences into the genome was evaluated with primers for neomycin-resistance gene in 27 the transposon, in reference with endogenous RNaseP gene. Real-time PCR analysis following 1 extraction and digestion of genomic DNA revealed that the number of integrated copies was 15 copies 2 per haploid genome in the Hela-attPlex4R clone. 3
The Hela-attPlex4R thus established was transfected with pTargetB-NLS-Rluc or pTargetB-4
LexA-Rluc with pCMV-int. Unfortunately, transfection with these vectors produced very few 5 blasticidin-resistant cells (data not shown), despite the fact that the donor vectors contained the 6 blasticidin-resistance gene. We redesigned the donor vector constructs so that they contained the attB 7 sequence at a different position (Fig. 6a) , taking into account a previous report that the location of the 8 attB sequences in the donor vectors affects sustained gene expression by the phiC31 integrase-based 9 vector system (Watanabe et al., 2011) . To minimize the effect on blasticidin-resistance gene expression, 10 the attB sequence was placed apart from the blasticidin-resistance gene in the newly developed donor 11 vector construct pTargetB2-NLS-Rluc (Fig. 6a) . As shown in Fig. 6b and c, transfection with 12 pTargetB2-NLS-Rluc and pCMV-int provided significantly more blasticidin-resistant colonies than 13 that with pTargetB-NLS-Rluc and pCMV-int. 14 Considering that displacement of the attB sequence was effective for increased expression 15 of the blasticidin-resistance gene, new donor vectors that expressed the Gal4-LexA DNA-binding 16 protein were constructed and designated pTargetB2(0x)-LexA-Rluc, pTargetB2(4x)-LexA-Rluc, 17 pTargetB2(18x)-LexA-Rluc, and pTargetB2(66x)-LexA-Rluc according to the number of UAS repeats 18 (Fig. 6a) . We expected that binding between the donor vectors and the Gal4-LexA DNA-binding 19 protein would become more likely as the number of UAS increases. 20
21
Integration site-specificity in chromosomal integration 22
To evaluate the integration site-specificity in chromosomal integration, Hela-attPlex4R cells 23
were transfected with pCMV-int and either pTargetB2-NLS-Rluc, pTargetB2(0x)-LexA-Rluc, 24 pTargetB2(4x)-LexA-Rluc, pTargetB2(18x)-LexA-Rluc, or pTargetB2(66x)-LexA-Rluc. To allow the 25 DNA-binding protein to be expressed and tether the donor vectors in advance, the cells were 26 transfected with the donor vectors 1 or 2 days prior to transfection with pCMV-int. After transfections 27 of pCMV-int, the cells were subjected to blasticidin selection and extraction of genomic DNA. 1
Quantitative PCR of genomic DNA was performed using forward and reverse primers designed to 2 anneal to a sequence neighboring the LexA operator and a sequence inside a donor vector, respectively. 3
These primers allowed us to count the copies of the donor vector integrated into the attP close to the 4 LexA operator sequence (Fig. 7a) . The copy number of total donor vectors was also evaluated as an 5 internal control. As for the 1-day delay of pCMV-int transfection, the targeted integration efficiency 6 of pTargetB2(4 ~ 18x)-LexA-Rluc was minimally higher than that of the negative controls (pTargetB2-7 NLS-Rluc and pTargetB2(0x)-LexA-Rluc) (Fig. 7b) . As for the 2 day delay of pCMV-int 8 transfection, the targeted integration efficiency of pTargetB2(4~18x)-LexA-Rluc was remarkably (up 9 to 26-fold) higher than that of the negative controls (Fig. 7c) . Unexpectedly, the targeted integration 10 efficiencies of pTargetB2(66x)-LexA-Rluc were lower than that of pTargetB2(4~18x)-LexA-Rluc 11 under both transfection conditions. 12 13
Confirmation of targeted integration by sequencing analysis 14
To confirm integration into the attP close to the LexA operator sequence, a plasmid rescue 15 method was adopted. First, Hela-attPlex4R cells were transfected with pTargetB2(4x)-LexA-Rluc and, 16 2 days later, with pCMV-int, and then selected by treatment with blasticidin. Secondly, genomic DNA 17 was extracted from the cells, digested with restriction enzymes, ligated, and used for E. coli 18 transformation. As pTargetB2(4x)-LexA-Rluc contains a blasticidin-resistance gene and E. coli 19 replication origin, fragments of genomic DNA containing an insertion of pTargetB2(4x)-LexA-Rluc 20 can be replicated in the presence of blasticidin. Of the obtained 2 clones of phiC31 integrase-mediated 21 integration products, one is the targeted integration product (Table 1) . Surprisingly, the other is 22 integrated into pseudo-attP in pCMV-int. Under the modified conditions, the donor vectors containing dual DNA-binding protein 12 provided a higher integration site-specificity than their negative controls in both the inter-plasmid 13 integration assay (Fig. 4b) and chromosomal integration assay (Fig. 7c) . In previous studies using 14 sequence-specific DNA-binding motifs, the fold increases of targeted chromosomal integration ranged 15 from 2.0 to 9.9 (Ivics et al., 2007 , Kettlun et al., 2011 , Owens et al., 2012 , Tan et al., 2006 , Voigt et 16 al., 2012 . Even though our data cannot simply be compared with the previous data because of the 17 differences in evaluation and analysis methods, a 26-fold increase in targeted chromosomal integration 18 (Fig. 7c) would be considerably large. However, the percentage of the donor vector integrated into 19 native attP (not pseudo-attP) neighboring the target sequence was not necessarily high (0.38% of tonal 20 donor vectors; Fig. 7b) . One reason for the low rate of targeted integration might be associated with 21 the context of attP-surrounding sequence (Calos, 2006) . The inter-plasmid integration assay showed 22 that the integration efficiency of pTargetB-NLS-Rluc into pAttP-lex4R was lowest among all recipient 23 vectors (Fig. 4a) . This suggests that the context of pAttP-lex4R-derived surrounding sequences might 24 not be suitable for phiC31 integrase-mediated integration. Therefore, if we select attP or pseudo-attP 25 sequences with more suitable surrounding contexts, the targeted integration percentage may increase. 26
In Hela-attPlex4R that was used for chromosomal integration assay, multiple target attP 27 sequences were inserted into the genome (15 copies per haploid genome). However, all the target attP 1 sites might not necessarily be available for transgene expression due to their surrounding chromosomal 2 contexts and epigenetic modifications. Selection of blasticidin-resistant cells could lead to 3 underestimation of the degree of site-specific chromosomal integration of pTargetB2-LexA-Rluc, 4 since it rules out integration to the target attP sites that do not allow the expression of the resistance 5 marker. Taking together with the existence of pseudo-attP sites in some regions of the genome such 6 as heterochromatin, it would be difficult to determine an exact efficiency count of targeted 7 chromosomal integration. Thus, it should be noted that the present assay method of targeted integration 8 simply allows relative comparison among the vector systems. 9
In the chromosomal integration assay, delayed transfection of the helper vector after that of 10 the donor vector transfections increased the difference between the pTargetB2(4~18x)-LexA-Rluc) 11 and the negative controls (pTargetB2-NLS-Rluc and pTargetB2(0x)-LexA-Rluc) (Fig. 7b, c) . These 12 results suggest that the time-lag transfection provides an opportunity for the DNA-binding proteins to 13 tether the donor vectors to the target sequences before phiC31 integrase-mediated integration. In 14 addition to time-lag transfection, the use of chemical-regulatable gene expression systems is another 15 option for producing an expression time-lag (Sharma et al., 2008 and Yen et al., 2004) . 16
Because of the simplicity of evaluation, the LexA operator sequence was selected as a target 17 sequence of the DNA-binding protein by inserting it into chromosomes exogenously. However, when 18 this targeted integration strategy is intended for practical applications such as gene therapies, the target 19 sequences should be selected from native genomic sequences. To achieve safer chromosomal 20 integration, pseudo-attP sequences in genomic safe harbors (Sadelain et al., 2012) should be selected 21 as integration sites, and a specific DNA-binding motif should be customized so that it binds near the 22 pseudo-attP sequences. In addition, it has been established that pseudo-attP sequences that can be 23 recognized as substrates for phiC31 integrase exhibit certain variations in chromosomal context among 24 cell types (Calos, 2006) . Selection of different target sequences might thus be required depending on 25 the cell types. 26
The present targeted integration approach is theoretically applicable to other integrative 27 with problem associated with the attB site (Fig. 6) , the design of donor vectors appears to be important 4 in targeted integration. As long as the vectors are carefully designed, the present targeted integration 5 approach would be useful for other integrative vector systems, including Sleeping Beauty and 6
piggyBac. 7
In conclusion, we demonstrated by using phiC31 integrase-based integration systems that a 8 multi-functional donor vector which expresses a sequence-specific dual DNA-binding protein that 9 tethers itself to the target sequence and which has multiple sequences for binding of the protein works 10 cooperatively with a helper vector when cells are subjected to both vector transfections separated by 11 an appropriate time lag. We believe that the present study provides important information toward the 12 achievement of site-specific transgene integration, and paves the way for more reliable gene therapies 13 and genetic studies. vector by recombining the attB and attP sequences. Because the donor vector is tethered to the target 5 sequence, its integration site is restricted to the vicinity of the target sequence. 6 7
Fig. 2 Vectors for targeted integration 8
Vector construction. Amp R , ampicillin-resistance gene; attB, attB sequence for phiC31 integrase-9 mediated recombination; attP, attP sequence for phiC31integrase-mediated recombination; Blast R , 10 blasticidin-resistance gene; CMV, cytomegalovirus promoter; EM7, bacterial EM7 promoter; Gal4, 11
Gal4 DNA-binding domain; hEF1, human elongation factor 1α promoter; LexA, LexA DNA-binding 12 domain; NLS, nuclear localization signal; Rluc, Renilla luciferase gene; Neo R , neomycin-resistance 13 gene; SV40, simian virus 40 promoter; ori, E. coli origin of replication; 4×UAS, four copies of 14 upstream activating sequences; Kan/Neo R , kanamycin/neomycin-resistance gene; LexA operator, 15
LexA operator sequence; SV40/BP, simian virus 40 promoter/Bacterial promoter. Each recipient 16 vector (pAttP-lex1~4F and 1~4R) has one copy of attP at 6.5-6.6 (1F, 1R), 1.7-1.8 (2F, 2R), 0.6-0. 
Supplementary Methods
pDNA construction
1. Construction of pIR-UAS-Rluc pIR-blastHGF was constructed as previously described (Nakanishi et al., 2010, Mol. Ther., 18, 707-714) . The UAS insert was created by PCR using the primers (AAATCGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCG TCGCGACGGAGTACTGTCC, CTATATTACCCTGTTATCCCTAGCGTAACTCGGAGGA CAGTACTCCGGTCGGAGGACAGTACTCCGTCGCGA). To construct pIR-UAS-HGF, pIR-blastHGF was digested with the restriction enzyme SwaI, and ligated with the UAS insert.
The Rluc cDNA insert was amplified by PCR using pRL-SV40 (Promega, Tokyo, Japan) as a template and the primers (CACCGGTATGACTTCGAAAGTTTATGATCCAGA, GCTCTAGAATCGATGAATTATTGTTCATTTTTGAGAACTCG). The Rluc cDNA insert was digested with restriction enzymes AgeI and XbaI. To construct pIR-UASRluc, pIR-UASHGF was digested with restriction enzymes AgeI and NheI, and ligated with the digested Rluc cDNA insert.
Construction of pTarget-NLS-Rluc
The NLS insert was created by PCR using the primers (GAAGATCTGGCGATCGCC GATCCTAAGAAGAAGCGCAAGGTGGGCGACCCGAAAAAGAAACGCAAAGTT, TTCCAATGCATTGGCTGCAGGTTTAAACGGAATTCttctcACCGGTACCAACTTTGCGTTTCT TTTTCGGG). To construct pET-NLS, the NLS insert and pET-42b (+) (Merk KGaA, Darmstadt, Germany) were digested with restriction enzymes BglII and PstI, and ligated.
To obtain the DNA fragment containing NLS, pET-NLS was digested with restriction enzymes SgfI and PmeI. To construct pBIND-NLS, the DNA fragments containing NLS and pFN11A (BIND) (Promega) digested with SgfI and PmeI were ligated.
pIR-UASRluc was digested with restriction enzymes SalI and MluI, and pBIND-NLS was digested with restriction enzymes BglII and FspI, respectively. To construct pTarget-NLS-Rluc-pre, these two digested pDNAs were blunted and ligated.
Two DNA fragments were created by PCR using pTarget-NLS-Rluc-pre as a template and two primer sets (ATGACTTCGAAAGTTTATGATCCAgaacaa + AGGTTTAGTTCCTGGTGTACTTGAgggggatg, GGCCGGCCAATTCGCTAGAGGGCCCTATTCTATAGTGTCA + CCGCGGATCTCAGGTAGGCGCCGGTCA). To construct pTarget-NLS-Rluc, these two DNA fragments were ligated.
3. Construction of pTarget-LexA-Rluc
The LexA DNA-binding domain (LexA-DBD) insert was amplified by PCR using pLexA-C bait vector (Dualsystems Biotech, Schlieren, Switzerland) as a template and primers (TCCCCCCGGGcgaaccagttggatgaaagcgtta, CGGAATTCtcacagccagtcgccgttgc). pTarget-NLS-Rluc was digested with restriction enzymes AgeI and EcoRI, and the LexA-DBD insert was digested with restriction enzymes XmaI and EcoRI. To construct pTarget-LexA-Rluc, the digested pTarget-NLS-Rluc and LexA-DBD insert were ligated.
4. Construction of pAttB-UAS-Rluc, pTargetB-NLS-Rluc, pTargetB-LexA-Rluc
The attB insert was amplified by PCR using pORF-luc-attB as template and primers (CGCGCACGTACGAAACCGAAGCGAATTTCGAGGTG, CGCGCACGTACGGCCGCTCGAGGCATCAAGCTAAT). pIR-UAS-Rluc, pTarget-NLS-Rluc, pTarget-LexA-Rluc and the attB insert were digested with restriction enzyme BsiWI. To construct pAttB-UAS-Rluc, pTargetB-NLS-Rluc and pTargetB-LexA-Rluc, the digested attB insert was ligated with digested pIR-UAS-Rluc, pTarget-NLS-Rluc and pTarget-LexA-Rluc, respectively.
Construction of pTargetB2(4x)-NLS-Rluc
The attB insert was prepared as described above. The attB insert was phosphorylated, and ligated with pTarget-NLS-Rluc digested with restriction enzyme BmgBI.
6. Construction of pTargetB2(4x)-LexA-Rluc pTargetB2(4x)-NLS-Rluc was digested with restriction enzymes BssHII and ApaLI, and the 2.8 kb DNA fragment containing the attB sequence was purified. pTarget-LexA-Rluc was digested with restriction enzymes BssHII and ApaLI, and the 5.1 kb DNA fragment containing the gene of the DNA-binding protein was purified. To obtain pTargetB2(4x)-LexA-Rluc, these purified DNA fragments were ligated.
7. Construction of pTargetB2(6, 10, 18, 34 and 66x)-LexA-Rluc pTargetB2(4x)-LexA-Rluc was digested with restriction enzymes SwaI and AvrII, and the 1.2 kb DNA fragment containing 4xUAS was purified. pTargetB2(4x)-LexA-Rluc was also digested with restriction enzymes NruI and AvrII, and the 6.7 kb DNA fragment containing 2xUAS was purified. To obtain pTargetB2(6x)-LexA-Rluc, these purified DNA fragments were ligated.
pTargetB2(10, 18, 34 and 66x)-LexA-Rluc was constructed by repeating the same procedure.
8. Construction of pTargetB2(0x)-LexA-Rluc pTargetB2(18x)-LexA-Rluc was digested with restriction enzymes SwaI and AvrII, and the 6.7 kb DNA fragment containing no UAS was purified. pIR-blastHGF was also digested with restriction enzymes SwaI and AvrII, and the 1.1 kb DNA fragment was purified. To obtain pTargetB2(0x)-LexA-Rluc, these DNA fragments were ligated.
9. Construction of pSV40-int pCMV-int (Addgene, Cambridge, MA, USA) was digested with restriction enzymes SpeI and NheI, and the DNA fragment containing the phiC31 integrase gene was purified. pRL-SV40 was digested with restriction enzymes NheI and XbaI, and the DNA fragment containing the SV40 promoter was purified. To construct pSV40-int, these DNA fragments were ligated.
10. Construction of pVITRO1-lexluc pCMV-luc was constructed as previously described (Nomura et al., 1999, Gene Ther., 6, 121-129) . The firefly luciferase gene flanked with the lexA operator sequence was amplified by PCR using pCMV-luc as a template and primers (CGGGATCCCTGTATATATATACAGATGGAAGACGCCAAAAACATAA, AAACGTACGCTAGTTACACGGCGATCTTTCC). To construct pVITRO1-lexluc, the PCR product and pVITRO1-neo-mcs (Invivogen, San Diego, CA, USA) were digested with restriction enzymes BamHI and BsiWI, and ligated.
Construction of pAttP-DsRed express
The whole DNA of pCMV-DsRed express (Takara Bio, Otsu, Japan) flanked with the attP sequence was amplified by PCR using pCMV-DsRed express as a template and primers (AGTTCTCTCAGTTGGGGGGCATTATGCCCAGTACATGACCTT, caaAGGTTACCCCAGTTGGGGcaggcgggccatttaccgtcatt). To construct pAttP-DsRed express, the PCR product was phosphorylated and self-ligated.
12. Construction of pAttP-lex1F pAttP-DsRed express was digested with restriction enzymes ApaLI and NdeI. The DNA fragment containing the attP sequence was purified and blunted. pVITRO1-lexluc was digested with restriction enzyme PsiI and the DNA fragment containing the LexA operator sequence was purified.
To construct pAttP-lex1F, the DNA fragments derived from pAttP-DsRed express and pVITRO1-lexluc were ligated.
Construction of pAttP-lex1R
pAttP-lex1F was digested with restriction enzymes ApaLI and NdeI. The DNA fragments were purified, blunted, and ligated. To obtain pAttP-lex1R, the pDNA with the attP sequence in a reverse orientation compared to pAttP-lex1F was selected from the ligation products.
14. Construction of pAttP-lex2F, 2R, 3F, 3R, 4F, 4R
To obtain pAttP0-lex, pAttP-lex1F was digested with restriction enzymes AfeI and ScaI, and the DNA fragment containing the LexA operator sequence was purified and self-ligated.
pAttP-lex1F was digested with restriction enzymes AfeI and ScaI, and the DNA fragment containing the attP sequence was purified. To construct pAttP-lex2F, 2R, 3F, 3R, 4F and 4R, the DNA fragment was ligated with pAttP0-lex digested with restriction enzyme SnaBI, SmaI or BstZ17I, respectively.
Construction of pIR-attPlex4Rt
The DNA containing the 3' and 5' inverted repeat sequences of piggyBac transposon was amplified by PCR using p3E1.2 (a gift from Prof. Hajime Mori, Kyoto Institute of Technology, Kyoto, Japan) as a template, and primers (AGAACTACCCATTTTATTATATATTAGTCACGA, AATACAACATGACTGTTTTTAAAGTACAAAAT). To construct pIR-attPlex4R, pAttP-lex4R was digested with restriction enzyme HindIII, phosphorylated, and ligated with the PCR product containing inverted repeat sequences of piggyBac transposon.
Construction of pVITRO1-neo-RnasePfragment
The DNA containing a part of the RNaseP gene was amplified by PCR using the Hela-attPlex4R genome as a template and primers (AGATTTGGACCTGCGAGCG, GAGCGGCTGTCTCCACAAGT). To obtain pVITRO1-neo-RNasePfragment, the PCR product was purified, phosphorylated, and ligated with pVITRO1-neo-mcs digested with restriction enzyme BstZ17I.
